Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Aragon Pharmaceuticals
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Nov 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 12 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.